Medical Advocates

Tipranavir (
Aptivus)
Pediatric Data

New and Noteworthy
FDA Updates
US Treatment Guidelines
Journal Data
Conference Data






 
 

Tipranavir Main Page  Main New/Newsworthy

Home Page

     

Last Update:  March 05, 2009 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     

February 2009
 

FDA/EU Updates
     


FDA Updates

       

     Label Updates
 
  PDF DOCUMENT
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information
on coadministration with midazolam

US FDA  June 23, 2008
Document

Journal Citations

       

 
A 12-year-old Boy with Multidrug-resistant Human Immunodeficiency Virus Type 1 Successfully Treated with
HAART Including Ritonavir-boosted Tipranavir Oral Solution and Enfuvirtide.
Feiterna-Sperling C, Walter H, Wahn V, Kleinkauf N.
Eur J Med Res
. 2009 Jan 28;14(1):44-6.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Tipranavir: a new protease inhibitor for the pediatric population.
Courter JD, Girotto JE, Salazar JC.
Expert Rev Anti Infect Ther
. 2008 Dec;6(6):797-803.
Abstract

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children
and adolescents.

Salazar JC, Cahn P, Yogev R, et al

AIDS
. 2008 Sep 12;22(14):1789-98.
Abstract


Conference Citations
 

XVII International AIDS Conference
 
14 CROI
 

XVI International AIDS Conference

 


Tipranavir Main Page  Main New/Newsworthy

Home Page

     

Tipranavir Pediatric Data